Company intelligence / Profile preview

Cadence OTC

Oakland, California, United States

Ownership: Private
Development stage: Other

Overview

Cadence OTC has a commercial product, the Morning After Pill (over-the-counter levonorgestrel), which is FDA approved and marketed nationwide as the #1 brand in convenience stores in 2024. They also market EarlyPT, an ultrasensitive pregnancy test. Their combination oral contraceptive pill, Zena, is awaiting FDA approval for OTC use.

Therapeutic areas: Women's Health
Modalities: Small moleculeCombination oral contraceptives
Industry: Biotech

Partnerships

Lil'Drug Store (distribution)

Beyond the preview

Go deeper on Cadence OTC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadence OTC.

Explore the full profile